

Accepted Manuscript

Beneficial action of resveratrol: How and why?

G.T. Diaz-Gerevini, G. Repositi, A. Dain, M.C. Tarres, U.N. Das, A.R. Eynard

PII: S0899-9007(15)00379-2

DOI: [10.1016/j.nut.2015.08.017](https://doi.org/10.1016/j.nut.2015.08.017)

Reference: NUT 9598

To appear in: *Nutrition*


Received Date: 6 April 2015

Revised Date: 6 August 2015

Accepted Date: 19 August 2015

Please cite this article as: Diaz-Gerevini GT, Repositi G, Dain A, Tarres MC, Das UN, Eynard AR, Beneficial action of resveratrol: How and why?, *Nutrition* (2015), doi: 10.1016/j.nut.2015.08.017.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Beneficial action of resveratrol: How and why?

Diaz-Gerevini GT^a, Repossi G^{a, b, c}, Dain A^a, Tarres MC^{c, d}, Das UN^{e, f},

Eynard AR^{a, c, *}

^aBiología Celular, Histología y Embriología, Facultad de Ciencias Médicas, INICSA
(CONICET-Universidad Nacional de Córdoba), Córdoba, Argentina;

Cátedra de Histología, Embriología y Genética, Universidad Nacional de La Rioja, La Rioja,
Argentina; ^cCONICET, Argentina;

^dFacultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina;

^eDepartment of Medicine, GVP Hospital and BioScience Research Centre, Campus of
Gayatri Vidya Parishad College of Engineering, Visakhapatnam, India;

^fUND Life Sciences, Federal Way, Washington 98003, USA

* Corresponding author:

Tel.: +54 351 433 4020; fax: +54 351 433 4021. E-mail address: aeynard@gmail.com (A. R. Eynard).

Abstract

Flavonoid resveratrol modulates transcription factor NF- κ B, cytochrome P450 isoenzyme CYP1A1, expression and activity of cyclooxygenase (COX) enzymes, Fas/Fas ligand mediated apoptosis, p53, mTOR and cyclins and various phosphodiesterases, which increases cytosolic cAMP that activates Epac1/CaMKK β /AMPK/SIRT1/PGC-1 α pathway that, in turn, facilitates increased oxidation of fatty acids, mitochondrial biogenesis, mitochondrial respiration, and gluconeogenesis. Resveratrol triggers apoptosis of activated T cells and suppresses tumor necrosis factor- α (TNF- α), interleukin-17 (IL-17) and other pro-inflammatory molecules and thus, is of benefit in autoimmune diseases. In addition, resveratrol inhibits expressions of (hypoxia inducible factor-1 α (HIF-1 α) and vascular endothelial growth factor (VEGF) explaining its effective action against cancer.

obesity, type 2 diabetes mellitus and metabolic syndrome is also altered in depression, schizophrenia, bipolar disorder, and autism. We noted that BDNF protects against cytotoxic actions of alloxan, streptozotocin and benzo(a)pyrene (BP). Resveratrol prevents bisphenol A (BSA)-induced autism, type 2 diabetes mellitus and metabolic syndrome suggesting that it may augment BDNF synthesis and action. We also observed that BDNF levels are low in type 2 diabetes mellitus (47) and BDNF enhances production of anti-inflammatory lipid: lipoxin A4, whose levels are low in diabetes mellitus. Thus, resveratrol may augment production of lipoxin A4. Resveratrol alters gut microbiota and influences stem cell proliferation and differentiation. These pleiotropic actions of resveratrol may explain the multitude of its actions and benefits.

Keywords: Resveratrol, flavonoids, type 2 diabetes mellitus, obesity, Alzheimer's disease, microbiota.

Introduction

The hypothesis that certain flavonoids such as resveratrol protect against dementia seen in elderly diabetic patients is interesting. The epidemic of obesity and type 2 diabetes mellitus that is sweeping both the developed and developing countries could be one reason for the increasing incidence of senile dementia. Consumption of high fat/high calorie diet, refined carbohydrates, and trans-fats and lack of adequate exercise is considered to be responsible for this epidemic of obesity and metabolic syndrome and consequent increase in the risk of coronary and cerebrovascular diseases, certain types of cancers, hypertension, and non-alcoholic fatty liver disease (NAFLD) and Alzheimer's disease (1-3). It has been suggested that an increase in the consumption of dietary fibre, flavonoids, anti-oxidant micronutrients and ω -3 polyunsaturated fatty acids (PUFAs) is beneficial. An imbalance in the modern dietary habit(s) as outlined above can lead to an increase in oxidative stress and endoplasmic reticulum (ER) stress that initiates the development of insulin resistance and onset of type 2 diabetes mellitus and Alzheimer's disease. Yorimitsu et al (4) showed that endomembranes progressively store misfolded proteins which causes ER stress, since unfolded proteins could trigger expression of chaperones resulting in autophagic cell death, included those of neuronal cells (5). Autophagic activity dysregulation is related to obesity and type 2 diabetes mellitus (6). ER stress and low-grade systemic inflammation seen in

obesity leads to impairment of insulin sensitivity pathway, peripheral insulin resistance and subsequent development of type 2 diabetes mellitus. This is supported by the work of Yin et al (7), who showed that adipocytes pre-loaded with the saturated fatty acid palmitate leads to endoplasmic reticulum stress and autophagy via protein kinase C-mediated signaling pathway independent of mammalian target of rapamycin (mTOR) (8).

Resveratrol has anti-oxidant actions and increases oxidation of fatty acids, mitochondrial biogenesis, mitochondrial respiration, and gluconeogenesis

One of the best ways to stem the epidemic of obesity, type 2 diabetes mellitus and Alzheimer's disease is to restrict calorie intake and do regular exercise that would lead to a decrease in endoplasmic reticulum stress. In this context, it is interesting to note that some of the beneficial actions of resveratrol seem to mimic several of the biochemical effects of calorie restriction. Resveratrol activates Sirtuin 1 (SIRT1) (9) and peroxisome proliferator-activated receptor- γ coactivator1 α (PGC-1 α) and improves the functioning of the mitochondria (10, 11). Recent studies have revealed that resveratrol binds to tyrosyl transfer-RNA (tRNA) synthetase (TyrRS) to potentiate a poly(ADP-ribose) polymerase 1 (PARP1)/NAD⁺ driven signaling cascade to activate p53 and AMPK by inhibiting SIRT1 (12). Cells treated with resveratrol showed a fourteen-fold increase in the action of superoxide dismutase (SOD) that removes superoxide anion, a potent free radical (13). SOD by reducing superoxide restores mitochondrial dysfunction to normal. Resveratrol by activating SIRT1 causes migration of FOXO transcription factors to the nucleus (14), which stimulates FOXO3a transcriptional activity (15) and was shown to enhance the sirtuin-catalyzed deacetylation (activity) of FOXO3a. SOD is a target of FOXO3a, and MnSOD expression is strongly induced in cells overexpressing FOXO3a (16). It is known that high expression of SOD but mild changes in catalase (CAT) and glutathione peroxidase (GPX) expression in cancer cells results in the mitochondrial accumulation of H₂O₂, which in turn induces cancer cell apoptosis (17). It appears that both exercise and resveratrol induce disproportional up-regulation of SOD, CAT and GPX to bring about their beneficial actions in cancer.

In addition, resveratrol modulates the transcription factor NF- κ B, inhibits the cytochrome P450 isoenzyme CYP1A1 and suppresses the expression and activity of cyclooxygenase (COX) enzymes, and modulates Fas/Fas ligand mediated apoptosis, p53, mTOR and cyclins A, B1, and cyclin-dependent kinases cdk 1 and 2 that may also account for its benefits (18-21). These actions of resveratrol (9-21) may be responsible for its benefit

in Alzheimer's disease (22). Resveratrol competitively inhibits various phosphodiesterases and thus, increases cytosolic cAMP, which acts as a second messenger for the activation of the pathway Epac1/CaMKK β /AMPK/SIRT1/PGC-1 α that facilitates an increase in oxidation of fatty acids, mitochondrial biogenesis, mitochondrial respiration, and gluconeogenesis (23, 24, see Figure 1).

Resveratrol has anti-inflammatory actions

On exposure to different immune stimuli, naïve T cells are activated, undergo proliferation and are made to undergo differentiation into three distinct functional subsets: T_{H1} cells produce IFN- γ and mediate protection against intracellular pathogens; whereas T_{H2} cells produce IL-4, IL-13 and IL-25 and are concerned with the clearance of extracellular pathogens; the third subset of T_{H17} cells produce IL-17 and are needed to clear extracellular pathogens not effectively handled by either T_{H1} or T_{H2} cells. T_{H17} cells defend the body against Gram-positive *Propionibacterium acnes*, the Gram-negative *Citrobacter rodentium*, *Klebsiella pneumoniae*, *Bacteroides spp.* and *Borrelia spp.*, the acid-fast *Mycobacterium tuberculosis*, and fungi such as *Candida albicans*. This wide spread response to a variety of organisms suggests that T_{H17} cells act as an early responsive immunocytes to a number of pathogens that are not handled appropriately by T_{H1}-or T_{H2}-type immunity (25). Thus, T_{H17} cells bridge the gap between innate and adaptive immunity. IL-17 producing T cells have profound pro-inflammatory effects and induce tissue damage. IL-17-deficient mice develop attenuated collagen-induced arthritis and experimental autoimmune encephalomyelitis (EAE); increased levels of IL-17 have been observed in patients with rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and psoriasis-evidences that strongly support the contention that IL-17 and T_{H17} cells play a significant role in autoimmune disorders (25-30). It is noteworthy that the ability of resveratrol to trigger apoptosis in activated T cells and downregulates tumor necrosis factor- α (TNF- α), interferon- γ (IFN- γ), interleukin (IL)-2, IL-9, IL-12, IL-17, macrophage inflammatory protein-1alpha (MIP-1alpha), and monocyte chemoattractant protein-1 (MCP-1) may explain its potential in the treatment of inflammatory and autoimmune diseases (31-35).

Both hypoxia-inducible factor-1 α (HIF-1 α) and vascular endothelial growth factor (VEGF) are overexpressed in many human tumors and their metastases, and are closely associated with a more aggressive tumor phenotype. Resveratrol inhibited the

expressions of HIF-1 α and VEGF implying that it could be an effective anticancer therapy for the prevention of cancer and metastasis (36-38).

Resveratrol is cytoprotective in nature

Increasing incidence of obesity and metabolic syndrome all over the world has been attributed not only to high-fat diet and lack of exercise but also to certain environmental factors such bisphenol-A (BPA), an endocrine disruptor present in plastic. A cross-sectional study performed in 76 out of 139 environmentally exposed adult males, unselected Caucasian subjects, enrolled by routine health survey at the "Federico II" University of Naples outpatient facilities, revealed that BPA and pro-inflammatory cytokine levels were significantly higher in subjects with visceral adiposity. BPA correlated with visceral obesity, triglycerides, glucose homeostasis and inflammatory markers. At the multivariate analysis WC and IL-6 remained the main predictors of BPA. These results supports that BPA and other environmental factors may play a role in visceral obesity-related low grade chronic inflammation (39). Similar association between BSA and autism has also been described (40).

In utero BPA exposure as a model environmental exposure has been shown to disrupt neurodevelopment and thus, cause autism. Studies suggested that prenatal BPA induced lasting DNA methylation changes in the transcriptionally relevant region of the *BDNF* gene in the hippocampus and blood of BALB/c mice. Similar BDNF methylation changes were also reported in the cord blood of humans exposed to high maternal BPA levels in utero (41). It is noteworthy that BDNF expression and DNA methylation are altered in several psychiatric disorders that are associated with early-life adversity, including depression, schizophrenia, bipolar disorder, and autism. BDNF is also involved in the pathogenesis of obesity, type 2 diabetes mellitus and metabolic syndrome (42) indicating that environmental agents could alter the expression and actions of BDNF that may lead to the development of several diseases. In this context, it is interesting to note that BDNF could function as a cytoprotective molecule preventing the cytotoxic actions of alloxan streptozotocin, benzo(a)pyrene (BP), an common environmental pollutant, and anti-cancer drug doxorubicin (Das UN, unpublished data). The protective action of BDNF against BP is especially interesting since it is a common mutagen and carcinogen found in coal tar, automobile exhaust fumes, cigarette smoke, cooked meat products, fried chicken, overcooked charcoal barbecued beef and hamburgers. Since, resveratrol is able to prevent BSA-induced autism, type 2 diabetes mellitus and metabolic syndrome (43-45); it is likely that it

(resveratrol) may have the ability to augment BDNF synthesis and action since BDNF also has similar beneficial actions in these diseases (42, 46). In a recent study, we noted that BDNF levels are low in subjects with type 2 diabetes mellitus (47) and that it interacts and enhances the production of an anti-inflammatory bioactive lipid namely, lipoxin A4, whose levels are also low in diabetes mellitus (47-49). Lipoxin A4 is a potent suppressor of pro-inflammatory prostaglandin E2 synthesis (50). This rises the interesting possibility that resveratrol may augment the production of lipoxin A4 and block that of prostaglandin E2 and thus, is able to bring about its beneficial actions in several diseases including autism, obesity, diabetes mellitus, metabolic syndrome, depression, schizophrenia and cancer (22, 24, 43-51).

There are two other potential mechanisms by which resveratrol acts: (i) by altering gut microbiota that have a role in several diseases and (ii) influencing stem cell proliferation and differentiation (52-55).

Conclusions

Despite many beneficial actions of resveratrol, one major concern is its poor solubility and absorption when given orally. Poor bioavailability of resveratrol is attributed to its extensive hepatic glucuronidation and sulfation. A recent study (56) revealed that in ApcMin mice (a model of colorectal carcinogenesis) that received a high-fat diet, the low resveratrol dose suppressed intestinal adenoma development more potently than did the higher dose. It was noted that the efficacy of resveratrol correlated with activation of AMPK and increased expression of the senescence marker p21. The nonlinear dose responses observed for AMPK and mechanistic target of rapamycin (mTOR) signaling in mouse adenoma cells correlated with the autophagy and senescence observed. Surprisingly, the effectiveness of low dose of resveratrol in protecting against colon cancer both in the mouse colon cancer cells and human colorectal tissues was found to be due to enhanced AMPK phosphorylation and autophagy and expression of the cytoprotective NAD(P)H dehydrogenase. These observations suggest that sometimes lower dose of diet-derived agents are more effective than higher doses to prevent cancer. These results emphasize the need to perform a dose response studies and develop better methods to deliver diet-derived chemopreventive molecules such as resveratrol reach the target tissues by using modern technologies such as microencapsulation or nanoparticles (57, 58) to derive their beneficial actions.

References

1. Knight JA. Diseases and disorders associated with excess body weight. *Ann Clin Lab Sci* 2011; **41**: 107-21.
2. Hu F B., Globalization of Diabetes The role of diet, lifestyle, and genes. *Diabetes Care* 2011; **34**: 1249–1257.
3. Lam DW, LeRoith D. The worldwide diabetes epidemic. *Curr Opin Endocrinol Diabetes Obes* 2012; **19**: 93-96.
4. Yorimitsu T, Nair U, Yang Z, Klionsky DJ. Endoplasmic reticulum stress triggers autophagy. *J Biol Chem* 2006; **281**: 30299-302304.
5. Juárez-Rojas JG, Reyes-Soffer G, Conlon D, Ginsberg HN. Autophagy and cardiometabolic risk factors. *Rev Endocr Metab Disord* 2014; **15**: 307-315.
- 6.- Stienstra R, Haim Y, Riahi Y, Netea M, Rudich A, Leibowitz G. Autophagy in adipose tissue and the beta cell: implications for obesity and diabetes. *Diabetologia* 2014; **57**: 1505-1516.
- 7.- Yin J, Wang Y, Gu L, Fan N, Ma Y, Peng Y. Palmitate induces endoplasmic reticulum stress and autophagy in mature adipocytes: Implications for apoptosis and inflammation. *Int J Mol Med* 2015; **35**: 932-940.
- 8.- Tan SH, Shui G, Zhou J, Li JJ, Bay BH, Wenk MR, Shen HM. Induction of autophagy by palmitic acid via protein kinase C-mediated signaling pathway independent of mTOR (mammalian target of rapamycin). *J Biol Chem* 2012; **287**: 14364-14376.
9. Alcáin FJ, Villalba JM. Sirtuin activators. *Expert Opin Ther Pat* 2009; **19**: 403–414.
10. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. *Cell* 2006; **127**: 1109-1122.
11. Denu JM. Fortifying the Link between SIRT1, Resveratrol, and mitochondrial function. *Cell Metabolism* 2012; **15**: 566-567.

12. Sajish M, Schimmel P. A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. *Nature* 2015; **519**: 370-373.
13. Robb EL, Page MM, Wiens BE, Stuart JA. Molecular mechanisms of oxidative stress resistance induced by resveratrol: Specific and progressive induction of MnSOD. *Biochem Biophys Res Commun* 2008; **367**: 406-412.
14. Stefani M, Markus MA, Lin RC, Pinese M, Dawes IW, Morris BJ. The effect of resveratrol on a cell model of human aging. *Annals NY Acad Sci* 2007; **1114**: 407-418.
15. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science* 2004; **303**: 2011-2015.
16. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffey PJ, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* 2002; **419**: 316-321.
17. Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ, et al. Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells. *Mol Cells* 2013; **35**: 219-225.
18. Leiro J, Arranz JA, Fraiz N, Sanmartín ML, Quezada E, Orallo F, et al. Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling. *Int. Immunopharmacol* 2005; **5**: 393-406.
19. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. *Biochem Biophys Res Commun* 1999; **262**: 20-24.
20. Cao Y, Fu ZD, Wang F, Liu HY, Han R. Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. *J Asian Nat Prod Res* 2005; **7**: 205-213.
21. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. *Cardiovasc Res* 2000; **47**: 549-555.
22. Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L. Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. *Biochim Biophys Acta* 2015; **1852**: 1202-1208.
23. Tennen RI, Michishita-Kioi E, Chua KF. Finding a target for resveratrol. *Cell* 2012; **148**: 387-389.

24. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. *Cell* 2012; **148**: 421–433.
25. Bettelli E, Kom T, Oukka M, Kuchroo VK. Induction and effector functions of T_H17 cells. *Nature* 2008; **453**: 1051–1057.
26. Margarita Dominguez-Villar M, Hafler DA. An Innate Role for IL-17. *Science* 2011; **332**: 47–48.
27. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. *J Immunol* 2003; **171**: 6173–6177.
28. Komiyama, Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. *J Immunol* 2006; **177**: 566–573.
29. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. *Gut* 2003; **52**: 65–70.
30. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, Nagarkatti P. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. *Mol Pharmacol* 2007; **72**: 1508–1521.
31. Imler TJ Jr, Petro TM. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression. *Int Immunopharmacol* 2009; **9**: 134–143.
32. Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G, Fuggetta MP. Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. *Inflammation* 2012; **35**: 240–248.
33. Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, McInnes IB, Xu D. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. *Ann Rheum Dis* 2012; **71**: 129–135.
34. Kjør TN, Thorsen K, Jessen N, Stenderup K, Pedersen SB. Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice. *PLoS One* 2015; **10**: e0126599.
35. Yao J, Wei C, Wang JY, Zhang R, Li YX, Wang LS. Effect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice. *World J Gastroenterol* 2015; **21**: 6572–6581.

36. Zhang M, Li W, Yu L, Wu S. The suppressive effect of resveratrol on HIF-1 α and VEGF expression after warm ischemia and reperfusion in rat liver. *PLoS One* 2014; **9**: e109589.
37. Seong H, Ryu J, Jeong JY, Chung IY, Han YS, Hwang SH, Park JM, Kang SS, Seo SW. Resveratrol suppresses vascular endothelial growth factor secretion via inhibition of CXCL-chemokine receptor 4 expression in ARPE-19 cells. *Mol Med Rep* 2015; **12**: 1479-1484.
38. Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. *Angiogenesis* 2010; **13**: 305-315.
39. Savastano S, Tarantino G, D'Esposito V, Passaretti F, Cabaro S, Liotti A, et al. Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population. *J Transl Med* 2015; **13**: 169.
40. Stein TP, Schluter MD, Steer RA, Guo L, Ming X. Bisphenol A exposure in children with autism spectrum disorders. *Autism Res* 2015; **8**: 272-283.
41. Kundakovic M, Gudsnuk K, Herbstman JB, Tang D, Perera FP, Champagne FA. DNA methylation of BDNF as a biomarker of early-life adversity. *Proc Natl Acad Sci U S A* 2015; **112**: 6807-6813.
42. Das UN. Obesity: Genes, brain, gut and environment. *Nutrition* 2010; **26**: 459-473.
43. Côté CD, Rasmussen BA, Duca FA, Zadeh-Tahmasebi M, Baur JA, Daljeet M, et al. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. *Nat Med* 2015; **21**: 498-505.
44. Duca FA, Côté CD, Rasmussen BA, Zadeh-Tahmasebi M, Rutter GA, Filippi BM, Lam TK. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. *Nat Med* 2015; **21**: 506-511.
45. Bambini-Junior V, Zanatta G, Della Flora Nunes G, Mueller de Melo G, Michels M, Fontes-Dutra M, et al. Resveratrol prevents social deficits in animal model of autism induced by valproic acid. *Neurosci Lett* 2014; **583**: 176-181.
46. Das UN. Autism as a disorder of deficiency of brain-derived neurotrophic factor and altered metabolism of polyunsaturated fatty acids. *Nutrition* 2013; **29**: 1175-1185.
47. Kaviarasan K, Mohanlal J, Mohammad Mulla MA, Shanmugam S, Sharma T, Das UN, Angayarkanni N. Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance as potential risk factors for diabetic retinopathy. *Metabolism*, in press.

Prostaglandins Leukot Essen Fatty Acids 2013; **88**: 201-210.

49. Umashankar V, Sathya B R, Kaviarasan K, Jithu M, Das UN, Angayarkanni N. Agonistic effect of polyunsaturated fatty acids (PUFAs) and its metabolites on brain-derived neurotrophic factor (BDNF) through molecular docking simulation. *Lipids Health Dis* 2012; **11**: 109.

50. Kumar R, Clerc AC, Gori I, Russell R, Pellegrini C, Govender L, Wyss JC, Golshayan D, Canny GO. Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. *PLoS One* 2014; **9**: e89742.

51. Sailaja P, Mani AM, Naveen KVG, Anasuya DH, Siresha B, Das UN. Effect of polyunsaturated fatty acids and their metabolites on bleomycin-induced cytotoxic action on human neuroblastoma cells *in vitro*. *PLoS One* 2014; **9**: e114766.

52. Qiao Y, Sun J, Xia S, Tang X, Shi Y, Le G. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. *Food Funct* 2014; **5**: 1241-1249.

53. Chen YB, Lan YW, Hung TH, Chen LG, Choo KB, Cheng WT, Lee HS, Chong KY. Mesenchymal stem cell-based HSP70 promoter-driven VEGFA induction by resveratrol promotes angiogenesis in a mouse model. *Cell Stress Chaperones* 2015; **20**: 643-652.

54. Pezzolla D, López-Beas J, Lachaud CC, Domínguez-Rodríguez A, Smani T, Hmadcha A, Soria B. Resveratrol ameliorates the maturation process of β -cell-like cells obtained from an optimized differentiation protocol of human embryonic stem cells. *PLoS One* 2015; **10**: e0119904.

55. Lee YL, Peng Q, Fong SW, Chen AC, Lee KF, Ng EH, Nagy A, Yeung WS. Sirtuin 1 facilitates generation of induced pluripotent stem cells from mouse embryonic fibroblasts through the miR-34a and p53 pathways. *PLoS One* 2012; **7**: e45633.

56. Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A, et al. Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. *Sci Transl Med* 2015; **7**: 298ra117.

57. Penalva R, Esparza I, Larraneta E, González-Navarro CJ, Gamazo C, Irache JM. Zein-Based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock. *J Agric Food Chem* 2015; **63**: 5603-5611.

58. da Rocha Lindner G, Bonfanti Santos D, Colle D, Gasnhar Moreira EL, Daniel Prediger R, Farina M, Khalil NM, Mara Mainardes R. Improved neuroprotective effects

of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. *Nanomedicine (Lond)* 2015; **10**: 1127-1138.

ACCEPTED MANUSCRIPT




Figure 1. Scheme showing various important actions of resveratrol that form the basis of its benefit in various diseases

Resveratrol activates Sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor- γ coactivator1 α (PGC-1 α) and improves the functioning of the mitochondria. Resveratrol binds to tyrosyl transfer-RNA (tRNA) synthetase (TyrRS) to potentiate a poly(ADP-ribose) polymerase 1 (PARP1)/NAD⁺ driven signaling cascade to activate p53 and AMPK by inhibiting SIRT1. Resveratrol induces mitochondrial accumulation of H₂O₂, which in turn induces cancer cell apoptosis. Resveratrol inhibits the production of pro-inflammatory IL-6, TNF- α and suppresses the activity of T_H17 cells and thus, is of benefit in several inflammatory conditions. It also inhibits the expressions of HIF-1 α and VEGF that may explain its ability to suppress cancer. Bisphenol has pro-inflammatory actions and may play a role in metabolic syndrome and autism that may be related to its ability to suppress BDNF and lipoxin A₄ synthesis and action. The beneficial actions of resveratrol and lipoxin A₄ in the amelioration of inflammation, suppression of prostaglanin E₂ synthesis and in the prevention of autism and metabolic syndrome implies that resveratrol may enhance the synthesis of lipoxin A₄ that needs to be confirmed.

- We review the action of resveratrol on multiple enzymes, transcription factors and metabolic pathways.
- Resveratrol effects include facilitation of increased oxidation of fatty acids, mitochondrial biogenesis, mitochondrial respiration, and gluconeogenesis.
- Resveratrol inhibits expressions of HIF-1 α and VEGF explaining its effective action against cancer.
- Resveratrol triggers apoptosis of activated T cells and suppresses pro-inflammatory molecules and thus, is of benefit in autoimmune diseases.
- Resveratrol alters gut microbiota and influences stem cell proliferation and differentiation.